Actuate to present at the h.c. wainwright 26th annual global investment conference

Chicago and fort worth, texas, sept. 05, 2024 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (“actuate” or the “company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and ewing sarcoma, through the inhibition of glycogen synthase kinase-3 beta (gsk-3Β), today announced that it will present at the h.c. wainwright 26th annual global investment conference taking place september 9-11, 2024 in new york city. in addition, the management team will be available for one-on-one meetings during the conference.
ACTU Ratings Summary
ACTU Quant Ranking